Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade

American Journal of Hypertension

Volumn 15, Issue 10 II, 2002, Pages

  Smith, David H G ^a,b,c  

^a Memorial Research Medical Clinic   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Integrated Research   (United States)

Author keywords

Angiotensin II receptor blockers; Hypertension; Olmesartan medoxomil

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; VALSARTAN;

BINDING AFFINITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CALCIUM ANTAGONISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STATISTICAL SIGNIFICANCE; VERTIGO;

EID: 0036793096     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(02)03005-4     Document Type: Review

References (43)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
2. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX, American Heart Association, 2001.
3. Stamler J, Viccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
4. Hansson L, Zanchetti AZ, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1751-1762.
5. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, Levy D: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-1227.
6. World Health Organization-International Society of Hypertension Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183.
7. Burt VL, Whelton P, Rocella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
8. Hyman DJ, Pavlik VN: Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-486.
9. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P: Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-1102.
10. Colhoun HM, Wei D, Poulter NR: Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-752.
11. Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, Gallois H, Cremier O: Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998;11:759-762.
12. Marques-Vidal P, Tuomilehto J: Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997;11:213-220.
13. Burnier M: Angiotensin type 1 receptor blockers. Circulation 2001;103:904-912.
14. Elliott HL: Angiotensin II antagonists: efficacy, duration of action, comparison with other drugs. J Hum Hypertens 1998;12:271-274.
15. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
16. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Anderson S, Arner P, for the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
17. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving H-H, Remizzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
18. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
19. Ball KJ, Williams PA, Stumpe KO: Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19(Suppl 1):S49-S56.
20. Neutel JM: Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C.
21. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J: Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-291, 318.
22. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
23. Kaplan NM: Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? J Hum Hypertens 2000;14(Suppl 1):S87-S90.
24. Carey RM, Zhi-Qin W, Siragy HM: Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-163.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
26. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
27. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN Group): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlöf B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
30. PROGRESS Collaborative Group: Randomised trial of a perindo-pril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
31. Ellis MS, Patterson JH: A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy 1996;16:849-860.
32. 1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995;92:10663-10667.
33. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;285:181-188.
34. Schwocho LR, Masonson HN: Pharmacokinetics of CS-866, a new angiotensin receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-527.
35. von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L: Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19(Suppl 1):S33-S40.
36. Laeis P, Puchler K, Kirch W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(Suppl 1):S21-S32.
37. Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN: Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (in press).
38. Van Mieghem W: A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension (Abstract). J Hypertens 2001;19(Suppl 1):S152.
39. Chrysant SG, Marbury T: The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. Am J Hypertens 2002;15:A57 (Abstract).
40. Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998;82(9B):9R-14R.
41. Kusek JW, Lee JY, Smith DE, Milligan S, Faulkner M, Cornell CE, Kopple JD, Greene PG: Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996;17(Suppl 4):40S-46S.
42. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
43. Neutel JM, Smith DHG, Weber MA: Efficacy of an olmesartan medoxomil-based treatment algorithm for hypertension control in practice-based settings. Am J Hypertens 2002;15:A56 (Abstract).